

Relative Difference in the Time-normalized Number of HAE Attacks Per Month/Year (Intention-to-Treat Analysis Set)

	CSL312 (N=39)	Placebo (N=25)
Study Period: 6-Month Treatment		
Total Number of HAE Attacks during Treatment Period	63	266
Number of Subjects with Treatment Period less than 30 Days; Missing Primary Endpoint, n (%) [1]	0	1 (4.0)
Number of Subjects with Treatment Period of at least 30 Days; Non-Missing Primary Endpoint, n (%) [1]	39 (100.0)	24 (96.0)
Number of HAE Attacks during Treatment Period	63	264
Mean Time-normalized Number of HAE Attacks Per Month	0.27	2.01
Mean Attack Ratio CSL312 to Placebo		0.13
Relative Difference in Means in the Time-normalized Number of HAE Attacks Per Month CSL312 to Placebo [2]		-86.51
95% Confidence Interval		(-95.68, -57.84)
Median Time-normalized Number of HAE Attacks Per Month	0.00	1.35
Median Attack Ratio CSL312 to Placebo		0.00
Relative Difference in Medians in the Time-normalized Number of HAE Attacks Per Month CSL312 to Placebo [3]		-100.00
95% Confidence Interval		(-, -)
Two-sided Wilcoxon Test, p-value (Hierarchical Testing H02)		<0.001

[1] Percentages are based on the Intention-to-Treat Analysis Set.

[2] Derived as: $100 * [(mean\ time-normalized\ number\ of\ HAE\ attacks\ for\ CSL312 - mean\ time\ normalized\ number\ of\ HAE\ attacks\ for\ Placebo) / mean\ time-normalized\ number\ of\ HAE\ attacks\ for\ Placebo]$.

[3] Derived as: $100 * [(median\ time-normalized\ number\ of\ HAE\ attacks\ for\ CSL312 - median\ time\ normalized\ number\ of\ HAE\ attacks\ for\ Placebo) / median\ time-normalized\ number\ of\ HAE\ attacks\ for\ Placebo]$.